Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governme… Read more
Market Cap & Net Worth: Evolutionary Genomics Inc (FNAM)
Evolutionary Genomics Inc (PINK:FNAM) has a market capitalization of $5.32K ($5.32K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #47810 globally and #14738 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evolutionary Genomics Inc's stock price $0.00 by its total outstanding shares 6655232 (6.66 Million).
Evolutionary Genomics Inc Market Cap History: 2015 to 2025
Evolutionary Genomics Inc's market capitalization history from 2015 to 2025. Data shows change from $16.64 Million to $5.32K (-59.06% CAGR).
Evolutionary Genomics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evolutionary Genomics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
585.66x
Evolutionary Genomics Inc's market cap is 585.66 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $16.64 Million | $262.92K | -$286.00K | 63.28x | N/A |
| 2016 | $23.29 Million | $221.58K | -$1.15 Million | 105.12x | N/A |
| 2017 | $6.66 Million | $32.69K | -$539.62K | 203.59x | N/A |
| 2018 | $1.66 Million | $114.81K | -$1.10 Million | 14.49x | N/A |
| 2019 | $9.98 Million | $122.69K | -$793.14K | 81.37x | N/A |
| 2020 | $7.32 Million | $12.50K | -$1.71 Million | 585.66x | N/A |
Competitor Companies of FNAM by Market Capitalization
Companies near Evolutionary Genomics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Evolutionary Genomics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Evolutionary Genomics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Evolutionary Genomics Inc's market cap moved from $16.64 Million to $ 5.32K, with a yearly change of -59.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.32K | 0.00% |
| 2024 | $5.32K | -99.82% |
| 2023 | $2.99 Million | -35.71% |
| 2022 | $4.66 Million | 0.00% |
| 2021 | $4.66 Million | -36.36% |
| 2020 | $7.32 Million | -26.67% |
| 2019 | $9.98 Million | +500.00% |
| 2018 | $1.66 Million | -75.00% |
| 2017 | $6.66 Million | -71.43% |
| 2016 | $23.29 Million | +40.00% |
| 2015 | $16.64 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Evolutionary Genomics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.32K USD |
| MoneyControl | $5.32K USD |
| MarketWatch | $5.32K USD |
| marketcap.company | $5.32K USD |
| Reuters | $5.32K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.